Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.

Abstract

De novo inhibitor development is a rare event in PTPs switched from pdFVIII to rFVIII. Based on previously published data of clinical studies a change in FVIII product is unlikely to provoke inhibitor formation.

Cite this paper

@article{Scharrer2001LackOE, title={Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.}, author={Inge Scharrer and Hartmut J. Ehrlich}, journal={Haemophilia : the official journal of the World Federation of Hemophilia}, year={2001}, volume={7 4}, pages={346-8} }